Ahmed Islam Sh, Hadi Ahmed Ma, Hassan Hassan H
Department of Ophthalmology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Department of Pediatrics and Neonatology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Eur J Ophthalmol. 2020 Jan;30(1):40-47. doi: 10.1177/1120672118812266. Epub 2018 Nov 15.
To report the results of treatment of type 1 prethreshold retinopathy of prematurity using intravitreal injection of ultra-low dose of ranibizumab (0.1 mg in 0.01 mL).
A retrospective observational case series study.
Review of files of eligible infants who received this form of treatment to determine the outcome of treatment and any associated ocular or systemic side effects.
The study included 24 eyes of 12 preterm infants with mean gestational age of 29.75 ± 1.54 weeks and mean birth weight of 1074.58 ± 320.59 g. A total of 22 eyes (91.67%) had zone II disease while 2 eyes of one infant (8.33%) had zone I disease. All cases showed regression of the signs of the active retinopathy of prematurity with complete retinal vascularization. None of the cases required retreatment. Three eyes developed ocular complications. Apart from mild feeding intolerance that lasted for 24 h after injection in one infant, none of the cases developed systemic side effects.
Intravitreal injection of ultra-low-dose ranibizumab showed promising efficacy and good ocular safety. However, further large-scale studies are required to give stronger evidence about the efficacy and safety of ultra-low-dose ranibizumab.
报告玻璃体内注射超低剂量雷珠单抗（0.01 mL中含0.1 mg）治疗1型阈值前早产儿视网膜病变的结果。
一项回顾性观察病例系列研究。
查阅接受这种治疗方式的符合条件婴儿的病历，以确定治疗结果以及任何相关的眼部或全身副作用。
该研究纳入了12例早产儿的24只眼，平均胎龄为29.75 ± 1.54周，平均出生体重为1074.58 ± 320.59 g。共有22只眼（91.67%）患有II区疾病，而一名婴儿的2只眼（8.33%）患有I区疾病。所有病例的早产儿视网膜病变活动体征均消退，视网膜完全血管化。无一例需要再次治疗。3只眼出现眼部并发症。除一名婴儿在注射后出现持续24小时的轻度喂养不耐受外，无一例出现全身副作用。
玻璃体内注射超低剂量雷珠单抗显示出有前景的疗效和良好的眼部安全性。然而，需要进一步的大规模研究来提供关于超低剂量雷珠单抗疗效和安全性的更有力证据。
